Abstract
The 2019 novel coronavirus disease (COVID-19), which is caused by the novel beta coronavirus, SARS-CoV-2, is currently prevalent all over the world, causing thousands of deaths with relatively high virulence. Like two other notable beta coronaviruses, severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 can lead to severe contagious respiratory disease. Due to impaired cellular immunity and physiological changes, pregnant women are susceptible to respiratory disease and are more likely to develop severe pneumonia. Given the prevalence of COVID-19, it is speculated that some pregnant women have already been infected. However, limited data are available for the clinical course and management of COVID-19 in pregnancy. Therefore, we conducted this review to identify strategies for the obstetric management of COVID-19. We compared the clinical course and outcomes of COVID-19, SARS, and MERS in pregnancy and discussed several drugs for the treatment of COVID-19 in pregnancy.
Highlights
The causative pathogen for COVID-19 was identified as a novel beta coronavirus, SARS-CoV-2, which is genetically related to severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV; Lu et al, 2020)
Cord blood, placenta, and the fetal membrane from pregnant women with COVID-19, SARS, and Middle East Respiratory Syndrome coronavirus (MERS) were all negative when tested with a viral nucleic acid test for SARSCoV-2, SARS-CoV-1, and MERS-CoV, respectively, in the studies included in our literature review
This research has provided some strategies for the obstetric management of pregnant women with COVID-19
Summary
After 18 days of treatment, her condition improved, and virus nucleic acid testing for SARS-CoV-2 was negative twice Most pregnant women presented with dyspnea (72.7%), cough (63.6%), and fever (54.5%); their chest radiographs revealed typical signs of viral infection. The woman infected in the first trimester continued pregnancy after her virus nucleic acid testing for MERS-Cov turned negative. The diagnosis of COVID-19 in pregnancy is mainly based on epidemiological history, clinical manifestations, chest radiography, and etiological tests (National Health Commission of the People’s Republic of China, 2020). This is similar to the evidence of diagnosis for SARS and MERS in pregnancy. The rate of preterm deliveries, low-birth-weight neonates, stillbirths, and birth defects did not increase (Roberts et al, 2009; Cohan et al, 2015)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
